A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1
125
about 3.4 years
18+
13 sites in CA, FL, GA +8
What this study is about
Researchers are testing a new drug called KTX-1001 to see if it's safe for people with multiple myeloma that has returned or not responded to other treatments. The trial will involve different groups of patients receiving varying combinations of the drug, including KTX-1001 alone and in combination with other medications like mezigdomide, carfilzomib, or pomalidomide.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cohort A1 & A2: KTX-1001
- 2.Take Cohort B1 & B2: KTX-1001+Mezigdomide
- 3.Take Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carfilzomib, pomalidomide
injection (Injection), oral (Oral Capsule)
Primary: Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD) Dose Expansion: Provide preliminary efficacy data on the antitumor effects of KTX-1001 in combination with other anti-myeloma therapy
Secondary: Pharmacokinetics & Pharmacodynamics KTX-1001± Combination Therapy
Oncology